Vaccine has emerged as a potent therapy against many diseases, such tumor. Nowadays, vaccines based on DNA, lymphocyte and peptides. Peptide-based vaccine can be well-designed and exactly controlled in vitro. The mainly challenges in development of peptide-based vaccine are specific antigen and effective system.
Based on previous research works on MUC1 glycopeptide vaccine, Prof. Yanmei Li research group recently reported a novel design of vaccine. MUC1 glycopeptides were conjugated to an aggregative domain through a peptide spacer. These vaccines aggregated into nanofibers in mild condition and partly simulated a carrier protein without probable side-effect. This work has been published in J. Am. Chem. Soc.2012, 134, 8730, and well estimated in Chem. Soc. Rev.2012. DOI: 10.1039/c2cs35413f
